ArticleSaudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society2024
Prevalence of carbapenem-resistant
Article in Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Prevalence of Carbapenem-Resistant Enterobacteriaceae in Intensive Care Units in Saudi Arabia:Saudi medical journal · 2026Pooled it
- Carbapenem-resistantPublic health in practice (Oxford, England) · 2026Review
- Antimicrobial Resistance Trends in Carbapenem-Resistant Enterobacterales in a Saudi Healthcare Setting.Microorganisms · 2026Article
- Carbapenem resistance in community-acquired urinary tract infections caused byJAC-antimicrobial resistance · 2026Article
- Emergence of aJournal of medical cases · 2026Article
- Epidemiology and carbapenemase gene distribution among carbapenem-resistant enterobacterales: a two-year retrospective study in a Saudi tertiary hospital.BMC microbiology · 2026Article
- Clinical outcomes and treatment effectiveness in patients with carbapenem-resistant Enterobacterales infections: a multicenter retrospective cohort study.Antimicrobial stewardship & healthcare epidemiology : ASHE · 2026Article
- Molecular epidemiology and mechanisms ofFrontiers in microbiology · 2026Article
- Patients and Surfaces: Integrated Clinical-Environmental Surveillance of MDR Gram-Negative Bacteria in Critical-Care Units (Karachi, 2024-2025).Microorganisms · 2025Article
- Nanomedicine approaches to enhance the effectiveness of meropenem: a strategy to tackle antimicrobial resistance.Discover nano · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Antimicrobial resistance is a significant public health issue. In addressing the threat of multidrug resistant bacterial infections, carbapenems have been used. The carbapenem-resistant
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.